OTCMKTS:TMED Trimedyne (TMED) Stock Price, News & Analysis $4.25 -0.01 (-0.23%) As of 03/20/2020 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Trimedyne Stock (OTCMKTS:TMED) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Trimedyne alerts:Sign Up Key Stats Today's Range$4.25▼$4.2550-Day Range$4.25▼$4.2552-Week Range$3.48▼$7.00Volume100 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTrimedyne, Inc. manufactures and sells lasers, and disposable and reusable fiber-optic laser devices for use in the medical field. It offers lasers, fibers, needles, and switch tips for use in orthopedics, urology, ear and nose surgery, throat surgery, gynecology, gastrointestinal surgery, general surgery, and other medical specialties. The company also provides 80 watt and 30 watt holmium lasers, and side firing laser needles to treat herniated or ruptured spinal discs. In addition, it engages in the provision of services, and rental of lasers and other medical equipment to hospitals and surgery centers on a fee-per-case basis. The company operates in Asia, Europe, Latin America, the Middle East, Australia, and internationally. It markets its products through commission sales representatives in the United States and independent distributors internationally. Trimedyne, Inc. was founded in 1980 and is based in Irvine, California.Read More… Remove Ads Receive TMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trimedyne and its competitors with MarketBeat's FREE daily newsletter. Email Address TMED Stock News HeadlinesTrimedyne (OTCMKTS:TMED) Share Price Crosses Below 200 Day Moving Average - Should You Sell?April 15 at 3:43 AM | americanbankingnews.comEGF Theramed Health Corp. (TMED.CN)August 26, 2024 | ca.finance.yahoo.comSee More Headlines TMED Stock Analysis - Frequently Asked Questions How have TMED shares performed this year? Trimedyne's stock was trading at $4.25 at the beginning of 2025. Since then, TMED stock has increased by 0.0% and is now trading at $4.25. View the best growth stocks for 2025 here. How were Trimedyne's earnings last quarter? Trimedyne, Inc. (OTCMKTS:TMED) issued its quarterly earnings results on Tuesday, February, 20th. The technology company reported $0.70 earnings per share (EPS) for the quarter. The technology company earned $1.53 million during the quarter. How do I buy shares of Trimedyne? Shares of TMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Trimedyne own? Based on aggregate information from My MarketBeat watchlists, some other companies that Trimedyne investors own include Aflac (AFL), Incyte (INCY), Martin Marietta Materials (MLM), National Fuel Gas (NFG), PDC Energy (PDCE), Snap (SNAP) and Agilent Technologies (A). Company Calendar Last Earnings2/20/2018Today4/16/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorComputer and Technology Industry Electromedical equipment Sub-IndustryN/A Current SymbolOTCMKTS:TMED CIK357001 Webwww.trimedyne.com Phone949-951-3800Fax949-855-8206EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (OTCMKTS:TMED) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?Recently, President Trump decided to kill the coin, for good reason. It now costs 4 cents to make a single pen...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trimedyne, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trimedyne With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.